Calpain 1 in neurodegeneration: a therapeutic target?

Lancet Neurol. 2016 Oct;15(11):1118. doi: 10.1016/S1474-4422(16)30175-2.

Authors

Ziv Gan-Or¹, Guy A Rouleau²

Affiliations

¹ Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Department of Human Genetics, McGill University, Montreal, Quebec, H3A 2B4, Canada. Electronic address: ziv.gan-or@mail.mcgill.ca.
² Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Department of Human Genetics, McGill University, Montreal, Quebec, H3A 2B4, Canada.

PMID: 27647640
DOI: 10.1016/S1474-4422(16)30175-2

No abstract available

Publication types

Letter

MeSH terms

Animals
Calpain / drug effects
Calpain / genetics
Calpain / metabolism*
Humans
Mutation / genetics
Neurodegenerative Diseases / genetics
Neurodegenerative Diseases / metabolism*
Neurodegenerative Diseases / therapy
Neuroprotective Agents / therapeutic use

Substances

Neuroprotective Agents
Calpain
CAPN1 protein, human